Thiazolidin-4-one-based compounds interfere with the eicosanoid biosynthesis pathways by mPGES-1/sEH/5-LO multi-target inhibition

[1]  V. Barone,et al.  Thiazolidin-4-one formation. Mechanistic and synthetic aspects of the reaction of imines and mercaptoacetic acid under microwave and conventional heating. , 2004, Organic & biomolecular chemistry.

[2]  A. Surrey.  The preparation of 4-thiazolidones by the reaction of thioglycolic acid with Schiff bases. , 1947, Journal of the American Chemical Society.

[3]  O. Werz,et al.  Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. , 2016, Journal of medicinal chemistry.

[4]  G. Bifulco,et al.  Discovery of 3-hydroxy-3-pyrrolin-2-one-based mPGES-1 inhibitors using a multi-step virtual screening protocol. , 2018, MedChemComm.

[5]  Eelco Ruijter,et al.  Multicomponent reaction design in the quest for molecular complexity and diversity. , 2011, Angewandte Chemie.

[6]  Asha V. Chate,et al.  Efficient approach to thiazolidinones via a one-pot three-component reaction involving 2-amino-1-phenylethanone hydrochloride, aldehyde and mercaptoacetic acid , 2016 .

[7]  G. Bifulco,et al.  A Combinatorial Virtual Screening Approach Driving the Synthesis of 2,4‐Thiazolidinedione‐Based Molecules as New Dual mPGES‐1/5‐LO Inhibitors , 2020, ChemMedChem.

[8]  E. Proschak,et al.  Phosphatase activity of soluble epoxide hydrolase. , 2017, Prostaglandins & other lipid mediators.

[9]  Birgit Schiøtt,et al.  Reaction mechanism of soluble epoxide hydrolase: insights from molecular dynamics simulations. , 2002, Journal of the American Chemical Society.

[10]  Samuel I. Miller,et al.  Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. , 2008, Journal of medicinal chemistry.

[11]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[12]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[13]  O. Werz,et al.  Selective upregulation of TNF&agr; expression in classically‐activated human monocyte‐derived macrophages (M1) through pharmacological interference with V‐ATPase , 2017, Biochemical pharmacology.

[14]  H. R. Salgado,et al.  Evolution of green chemistry and its multidimensional impacts: A review , 2018, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[15]  Patrik Johansson,et al.  Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily , 2013, Proceedings of the National Academy of Sciences.

[16]  Shobha N. Bhattachar,et al.  Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. , 2016, Journal of medicinal chemistry.

[17]  S. Hwang,et al.  Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative , 2021, Journal of medicinal chemistry.

[18]  D. Christianson,et al.  Human soluble epoxide hydrolase: Structural basis of inhibition by 4‐(3‐cyclohexylureido)‐carboxylic acids , 2006, Protein science : a publication of the Protein Society.

[19]  Wolfgang Albrecht,et al.  Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  S. Cuzzocrea,et al.  5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents. , 2005, Bioorganic & medicinal chemistry.

[21]  O. Werz,et al.  Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. , 2015, Biochemical pharmacology.

[22]  M. Abdelgawad,et al.  Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. , 2016, Bioorganic chemistry.

[23]  G. Fan,et al.  Roles of resolvins in the resolution of acute inflammation , 2015, Cell biology international.

[24]  S. Hwang,et al.  Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis , 2019, Front. Pharmacol..

[25]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[26]  Joseph Cheriyan,et al.  Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.

[27]  P. Jakobsson,et al.  A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. , 2019, Prostaglandins & other lipid mediators.

[28]  B D Hammock,et al.  Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. , 1988, Analytical biochemistry.

[29]  S. T. A. Shah,et al.  Crystallizing Membrane Proteins in the Lipidic Mesophase. Experience with Human Prostaglandin E2 Synthase 1 and an Evolving Strategy , 2014, Crystal growth & design.

[30]  M. Gopalakrishnan,et al.  Three component one-pot synthesis of novel pyrimidino thiazolidin-4-ones catalyzed by activated fly ash , 2009 .

[31]  D. Christianson,et al.  Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Sandra K. Wittmann,et al.  Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase , 2017, Scientific Reports.

[33]  G. Bifulco,et al.  Targeting mPGES-1 by a Combinatorial Approach: Identification of the Aminobenzothiazole Scaffold to Suppress PGE2 Levels. , 2020, ACS medicinal chemistry letters.

[34]  Paul D. Jones,et al.  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. , 2011, Bioorganic & medicinal chemistry letters.

[35]  G. Bifulco,et al.  Identification of novel microsomal prostaglandin E2 synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening. , 2017, European journal of medicinal chemistry.

[36]  O. Werz,et al.  Natural products as inhibitors of prostaglandin E2 and pro-inflammatory 5-lipoxygenase-derived lipid mediator biosynthesis. , 2018, Biotechnology advances.

[37]  X. Wan,et al.  Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer , 2016, Tumor Biology.

[38]  G. Bifulco,et al.  Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E₂ synthase-1 enzyme (mPGES-1). , 2014, European journal of medicinal chemistry.

[39]  C. Wheelock,et al.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. , 2002, Biochemical pharmacology.